Methods of treating leukemia
AssigneeBioChem Pharma Inc.
InventorsHenriette Gourdeau, Francis J. Giles
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkynyl, C2-6 alkynyl and an hydroxy protecting group; and wherein said compound is substantially in the form of the (−) enantiomer.
Claims41
A method for treating leukemia in a host comprising administering to the host having leukemia synergistically a therapeutically effective amount of doxorubucin and at least one compound of general formula I
- wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and
- wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and hydroxy protecting groups, and wherein said compound is substantially in the form of the (−) enantiomer.
A pharmaceutical composition comprising a synergistically effective amount of doxorubicin and at least one compound of formula I
- wherein
- B is cytosine or 5-fluorocytosine,
- R is H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, or
- Rc is in each case independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or a hydroxy protecting group, and wherein said compound is substantially in the form of the (−) enantiomer.
A pharmaceutical combination comprising a synergistically effective amount of doxorubicin and at least one compound of formula I
- wherein
- B is cytosine or 5-fluorocytosine,
- R is H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, or
- Rc is in each case independently H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl or a hydroxy protecting group, and wherein said compound is substantially in the form of the (−) enantiomer.
Dependencies are inferred from the claim text.